List view / Grid view

European Pharmaceutical Review


Raman supplement 2011

24 October 2011 | By

In this Raman supplement: Solid state transformations of APIS during manufacturing by Raman analysis of pharmaceutical molecules and dosage forms; Detection, determination of chemical composition and chemical profiling of counterfeit medicines...

eLN supplement 2011

31 August 2011 | By

In this eLN supplement: eLNs - An essential productivity tool - but which one to use?; Using an eLN to create GMP compliant records for drug substance manufacture; Implementation of an electronic lab notebook system at VIB; eLN roundtable...

Under the microscope: Steve Delity

31 August 2011 | By

Rapid Micro Biosystems is a privately owned, venture backed company with headquarters in Bedford, Massachusetts. Since launching its GrowthDirect™ System in 2008, the company has now moved into Europe with the opening of its new demo centre in Darmstadt, Germany in June 2011. So, how does CEO Steve Delity view…

Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke

28 August 2011 | By

New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…

KOMBIGLYZE™ XR tablets approved in the US for the treatment of type 2 diabetes mellitus in adults

5 November 2010 | By

AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across…

Corning to acquire Plaslab S.A.S.

13 August 2010 | By

Corning Incorporated (NYSE:GLW) announced today that it has reached an agreement with the shareholders of Plaslab S.A.S. to acquire all outstanding shares of the company. Assuming certain closing conditions are met, the acquisition is expected to be completed in the fourth quarter of 2010.

G:BOX Chemiluminescence Imager is used at Prestigious Research Institute to rapidly determine the pre-clinical potential of anti-cancer compounds

29 September 2009 | By

Syngene, a world-leading manufacturer of image analysis solutions, is proud to announce its G:BOX chemiluminescence imaging system is being used by scientists at one of Scotland’s top Universities, Edinburgh Napier University in Edinburgh to accurately determine the effectiveness of novel anti-cancer therapies.

Stem Cells Roundtable

20 March 2009 | By

Dr Paul Andrews (Senior Scientist, ITI Stem Cell Technology Programme, University of Dundee), Professor Peter Andrews (co-Director of the Centre for Stem Cell Biology, University of Sheffield), Fergus McKenzie PhD. (Programme Manager, ITI-Life Sciences), Dr Stephen Minger (Senior Lecturer in Stem Cell Biology, Kings College London) and Will Rust (Section…

Roundtable: The future direction for clinical trials

21 September 2007 | By

Sally Burtles, Stephen Freestone and Eddie Caffrey discuss the future direction for clinical trials, covering the main challenges faced in the current application of Phase I clinical trials, changes the industry be implementing in order to further improve the efficiency of early clinical trials and how the Regulatory bodies’ guidance…

Send this to a friend